250 related articles for article (PubMed ID: 29843122)
1. Comprehensive and Integrative Analysis Reveals the Diagnostic, Clinicopathological and Prognostic Significance of Polo-Like Kinase 1 in Hepatocellular Carcinoma.
Lin P; Wen DY; Dang YW; He Y; Yang H; Chen G
Cell Physiol Biochem; 2018; 47(3):925-947. PubMed ID: 29843122
[TBL] [Abstract][Full Text] [Related]
2. Polo-like kinase 1 as a promising diagnostic biomarker and potential therapeutic target for hepatocellular carcinoma.
Yousef EH; El-Mesery ME; Habeeb MR; Eissa LA
Tumour Biol; 2020 Apr; 42(4):1010428320914475. PubMed ID: 32252611
[TBL] [Abstract][Full Text] [Related]
3. [Expression and prognostic value of Polo-like kinase 1, E-cadherin in the patients with hepatocellular carcinoma].
Chen XJ; Wu LM; Xu XB; Feng XW; Xie HY; Zhang M; Shen Y; Wang WL; Liang TB; Zheng SS
Zhonghua Wai Ke Za Zhi; 2007 Oct; 45(19):1354-8. PubMed ID: 18241575
[TBL] [Abstract][Full Text] [Related]
4. CDK1-PLK1/SGOL2/ANLN pathway mediating abnormal cell division in cell cycle may be a critical process in hepatocellular carcinoma.
Li L; Huang K; Zhao H; Chen B; Ye Q; Yue J
Cell Cycle; 2020 May; 19(10):1236-1252. PubMed ID: 32275843
[TBL] [Abstract][Full Text] [Related]
5. ECT2 overexpression promotes the polarization of tumor-associated macrophages in hepatocellular carcinoma via the ECT2/PLK1/PTEN pathway.
Xu D; Wang Y; Wu J; Zhang Z; Chen J; Xie M; Tang R; Chen C; Chen L; Lin S; Luo X; Zheng J
Cell Death Dis; 2021 Feb; 12(2):162. PubMed ID: 33558466
[TBL] [Abstract][Full Text] [Related]
6. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway.
Zhang C; Wang X; Fang D; Xu P; Mo X; Hu C; Abdelatty A; Wang M; Xu H; Sun Q; Zhou G; She J; Xia J; Hui KM; Xia H
Theranostics; 2021; 11(5):2108-2122. PubMed ID: 33500714
[No Abstract] [Full Text] [Related]
7. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.
Mok WC; Wasser S; Tan T; Lim SG
World J Gastroenterol; 2012 Jul; 18(27):3527-36. PubMed ID: 22826617
[TBL] [Abstract][Full Text] [Related]
8. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation of ACP1, BMP4, and TSPYL5 in Hepatocellular Carcinoma and Their Potential Clinical Significance.
Qiu X; Hu B; Huang Y; Deng Y; Wang X; Zheng F
Dig Dis Sci; 2016 Jan; 61(1):149-57. PubMed ID: 26386860
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients.
He ZL; Zheng H; Lin H; Miao XY; Zhong DW
World J Gastroenterol; 2009 Sep; 15(33):4177-82. PubMed ID: 19725153
[TBL] [Abstract][Full Text] [Related]
11. Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma.
Wang XQ; Zhu YQ; Lui KS; Cai Q; Lu P; Poon RT
Clin Cancer Res; 2008 Nov; 14(21):6813-20. PubMed ID: 18980975
[TBL] [Abstract][Full Text] [Related]
12. Dual targeting of Polo-like kinase 1 and baculoviral inhibitor of apoptosis repeat-containing 5 in TP53-mutated hepatocellular carcinoma.
Li Y; Zhao ZG; Luo Y; Cui H; Wang HY; Jia YF; Gao YT
World J Gastroenterol; 2020 Aug; 26(32):4786-4801. PubMed ID: 32921957
[TBL] [Abstract][Full Text] [Related]
13. Utility of miR‑133a‑3p as a diagnostic indicator for hepatocellular carcinoma: An investigation combined with GEO, TCGA, meta‑analysis and bioinformatics.
Liang HW; Yang X; Wen DY; Gao L; Zhang XY; Ye ZH; Luo J; Li ZY; He Y; Pang YY; Chen G
Mol Med Rep; 2018 Jan; 17(1):1469-1484. PubMed ID: 29138825
[TBL] [Abstract][Full Text] [Related]
14. [Polo like kinase 1 expression and prognostic value in gastric carcinomas].
Lan B; Liu BY; Chen XH; Qu Y; Zhang XQ; Cai Q; Zhu ZG
Zhonghua Wei Chang Wai Ke Za Zhi; 2007 Jan; 10(1):70-2. PubMed ID: 17253180
[TBL] [Abstract][Full Text] [Related]
15. Polo-like kinase 1 expression is a prognostic factor in human colon cancer.
Weichert W; Kristiansen G; Schmidt M; Gekeler V; Noske A; Niesporek S; Dietel M; Denkert C
World J Gastroenterol; 2005 Sep; 11(36):5644-50. PubMed ID: 16237758
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological and prognostic implications of polo-like kinase 1 expression in colorectal cancer: A systematic review and meta-analysis.
Ran Z; Chen W; Shang J; Li X; Nie Z; Yang J; Li N
Gene; 2019 Dec; 721():144097. PubMed ID: 31493507
[TBL] [Abstract][Full Text] [Related]
17. Cyclin B2 Overexpression in Human Hepatocellular Carcinoma is Associated with Poor Prognosis.
Li R; Jiang X; Zhang Y; Wang S; Chen X; Yu X; Ma J; Huang X
Arch Med Res; 2019 Jan; 50(1):10-17. PubMed ID: 31101236
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma.
Pellegrino R; Calvisi DF; Ladu S; Ehemann V; Staniscia T; Evert M; Dombrowski F; Schirmacher P; Longerich T
Hepatology; 2010 Mar; 51(3):857-68. PubMed ID: 20112253
[TBL] [Abstract][Full Text] [Related]
19. Analyses of expressions and prognostic values of Polo-like kinases in non-small cell lung cancer.
Zeng Y; Li N; Liu W; Zeng M; Cheng J; Huang J
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2447-2460. PubMed ID: 32627077
[TBL] [Abstract][Full Text] [Related]
20. Potential role of microRNA‑223‑3p in the tumorigenesis of hepatocellular carcinoma: A comprehensive study based on data mining and bioinformatics.
Zhang R; Zhang LJ; Yang ML; Huang LS; Chen G; Feng ZB
Mol Med Rep; 2018 Feb; 17(2):2211-2228. PubMed ID: 29207133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
